Is pathogenic humoral autoimmunity a Th1 response? Lessons from (for) myasthenia gravis

Immunology Today

Volumn 21, Issue 1, 2000, Pages 19-23

  Balasa, Balaji ^a   Sarvetnick, Nora ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; AUTOANTIGEN; CD27 ANTIGEN; CD4 ANTIGEN; CHOLINERGIC RECEPTOR; CHOLINERGIC RECEPTOR ANTIBODY; CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 12; INTERLEUKIN 4; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; NICOTINIC RECEPTOR; OKT 4;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTOIMMUNITY; B LYMPHOCYTE; CELL INTERACTION; CONTROLLED STUDY; CYTOKINE PRODUCTION; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMORAL IMMUNE DEFICIENCY; IMMUNOPATHOGENESIS; MOUSE; MYASTHENIA GRAVIS; NEUROMUSCULAR SYNAPSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROMOTER REGION; RAT; T LYMPHOCYTE ACTIVATION; T LYMPHOCYTE SUBPOPULATION; TH1 CELL; TH2 CELL;

EID: 0034131406     PISSN: 01675699     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0167-5699(99)01553-4     Document Type: Note

References (53)

1. 1 Christadoss, P. (1989) Immunogenetics of experimental autoimmune myasthenia gravis. Crit. Rev. Immunol. 9, 247-278
2. 2 Lindstrom, J. et al. (1988) Myasthenia gravis. Adv. Immunol. 42, 233-284
3. 3 Hawke, S. et al. (1996) Autoimmune T cells in myasthenia gravis: heterogeneity and potential for specific immunotargeting. Immunol. Today 17, 307-311
4. 4 Conti-Tronconi, B.M. et al. (1994) The nicotinic acetylcholine receptor: structure and autoimmune pathology. Crit. Rev. Biochem. Mol. Biol. 29, 69-123
5. 5 Vincent, A. et al. (1993) Seronegative myasthenia gravis. Evidence for plasma factor(s) interfering with acetylcholine receptor function. Ann. New York Acad. Sci. 681, 529-538
6. 6 Berman, P.W. and Patrick, J. (1980) Experimental myasthenia gravis. A murine system. J. Exp. Med. 151, 204-223
7. 7 Lennon, V.A. et al. (1975) Experimental myasthenia gravis: a model of myasthenia gravis in rats and guinea pigs. J. Exp. Med. 141, 1365-1375
8. 8 Christadoss, P. and Dauphinee, M.J. (1986) Immunotherapy for myasthenia gravis: a murine model. J. Immunol. 136, 2436-2440
9. 9 Kaul, R. et al. (1994) Major histocompatibility complex class II gene disruption prevents experimental autoimmune myasthenia gravis. J. Immunol. 152, 3152-3157
10. + T cells are essential to induce experimental autoimmune myasthenia gravis. J. Exp. Med. 184, 349-356
11. 11 Yokoi, T. et al. (1987) T lymphocyte recognition of acetylcholine receptor: localization of the full T cell recognition profile on the extracellular part of the alpha chain of Torpedo californica acetylcholine receptor. Eur. J. Immunol. 17, 1697-1702
12. 12 Bellone, M. et al. (1991) Experimental myasthenia gravis in congenic mice. Sequence mapping and H-2 restriction of T helper epitopes on the alpha subunits of Torpedo californica and murine acetylcholine receptors. Eur. J. Immunol. 21, 2303-2310
13. 13 Rosenberg, J.S. et al. (1996) B-cell activation in vitro by helper T cells specific to region alpha 146-162 of Torpedo californica nicotinic acetylcholine receptor. J. Immunol. 157, 3192-3199
14. 14 Shenoy, M. et al. (1994) Effect of MHC class I and CD8 cell deficiency on experimental autoimmune myasthenia gravis pathogenesis. J. Immunol. 152, 5330-5335
15. 15 Hohlfeld, R. et al. (1982) T-lymphocytes in experimental autoimmune myasthenia gravis. Isolation of T-helper cell lines. J. Neurol. Sci. 57, 265-280
16. 16 Lindstrom, J.M. et al. (1976) Pathological mechanisms in experimental autoimmune myasthenia gravis. II. Passive transfer of experimental autoimmune myasthenia gravis in rats with anti-acetylcholine receptor antibodies. J. Exp. Med. 144, 739-753
17. 17 Christadoss, P. (1988) C5 gene influences the development of murine myasthenia gravis. J. Immunol. 140, 2589-2592
18. + T cells in the pathogenesis of organ-specific autoimmune diseases. Immunol. Today 16, 34-38
19. 19 Link, J. et al. (1994) Organ-specific autoantigens induce interferon-γ and interleukin-4 mRNA expression in mononuclear cells and myasthenia gravis. Neurology 44, 728-734
20. 20 Yang, B. et al. (1998) How subtle differences in MHC class II affect the severity of experimental myasthenia gravis. Clin. Immunol. Immunopathol. 86, 45-58
21. 21 Meager, A. et al. (1997) Spontaneous neutralising antibodies to interferon-alpha and interleukin-12 in thymoma-associated autoimmune disease. Lancet 350, 1596-1597
22. 22 Link, H. et al. (1991) Acetylcholine receptor-reactive T and B cells in myasthenia gravis and controls. J. Clin. Invest. 87, 2191-2196
23. 23 Wu, B. et al. (1997) Tolerance to a dominant T cell epitope in the acetylcholine receptor molecule induces epitope spread and suppresses murine myasthenia gravis. J. Immunol. 159, 3016-3023
24. 24 Karachunski, P. et al. (1997) Prevention of experimental myasthenia gravis by nasal administration of synthetic acetylcholine receptor T epitope sequences. J. Clin. Invest. 100, 3027-3035
25. 25 Wang, Z-Y. et al. (1993) T-cell immunity to acetylcholine receptor and its subunits in Lewis rats over the course of experimental autoimmune myasthenia gravis. Scand. J. Immunol. 37, 615-622
26. 26 Wang, Z.Y. et al. (1997) Th1 epitope repertoire on the alpha subunit of human muscle acetylcholine receptor in myasthenia gravis. Neurology 48, 1643-1653
27. 27 Wang, Z.Y. et al. (1998) T-cell recognition of muscle acetylcholine receptor subunits in generalized and ocular myasthenia gravis. Neurology 50, 1045-1054
28. + epitopes. J. Immunol. 152, 4686-4698
29. 29 Nagvekar, N. et al. (1998) A pathogenic role for the thymoma in myasthenia gravis: autosensitization of IL-4 producing T cell clones recognizing extracellular acetylcholine receptor epitopes presented by minority class II epitopes. J. Clin. Invest. 101, 2268-2277
30. 30 Gu, D. et al. (1995) Myasthenia gravis-like syndrome induced by expression of interferon γ at the neuromuscular junction. J. Exp. Med. 181, 547-557
31. 31 Balasa, B. et al. Interferon γ (IFN-γ) is necessary for the genesis of acetylcholine receptor-induced clinical experimental autoimmune myasthenia gravis in mice. J. Exp. Med. 186, 385-391
32. 32 Zhang, G-X. et al. (1996) Autoreactive T cell responses and cytokine patterns reflect resistance to experimental autoimmune myasthenia gravis in Wistar Furth rats. Eur. J. Immunol. 26, 2552-2558
33. 33 Wang, Z.Y. et al. (1993) T cell reactivity to acetylcholine receptor in rats orally tolerized against experimental autoimmune myasthenia gravis. Cell. Immunol. 152, 394-404
34. 34 Ma, C.G. et al. (1995) Suppression of experimental autoimmune myasthenia gravis by nasal administration of acetylcholine receptor. J. Neuroimmunol. 58, 51-60
35. 35 Moiloa, L. et al. (1998) IL-12 is involved in the induction of experimental autoimmune myasthenia gravis, an antibody-mediated disease. Eur. J. Immunol. 28, 2487-2497
36. 36 Balasa, B. et al. (1998) The Th2 cytokine IL-4 is not required for the progression of antibody-dependent autoimmune myasthenia gravis. J. Immunol. 161, 2856-2862
37. 37 Halloran, P.F. et al. (1992) Local T cell responses induce widespread MHC expression. Evidence that IFN-γ induces its own expression in remote sites. J. Immunol. 148, 3837-3846
38. 38 Mitchell, T.J. et al. (1996) IFN-γ up-regulates expression of the complement C3 and C4 by stabilization of mRNA. J. Immunol. 156, 4429-4434
39. 39 Bradley, L.M. et al. (1996) A direct role for IFN-γ in regulation of Th1 cell development. J. Immunol. 157, 1350-1358
40. 40 Wheatley, L.M. et al. (1992) Molecular evidence for the expression of nicotinic acetylcholine receptor alpha-chain in the mouse thymus. J. Immunol. 148, 3105-3109
41. 41 Salmon, A-M. et al. (1998) An acetylcholine receptor alpha subunit promoter confers intrathymic expression in transgenic mice. Implications for tolerance of a transgenic self-antigen and for autoreactivity in myasthenia gravis. J. Clin. Invest. 101, 2340-2350
42. 42 Roy, M. et al. (1995) Studies on the interdependence of gp39 and B7 expression and function during antigen-specific immune responses. Eur. J. Immunol. 25, 596-603
43. 43 Linsley, P.S. et al. (1992) Immunosuppression in vivo by a soluble form of the CTLA-4 T cell activation molecule. Science 257, 792-795
44. 44 Han, S. et al. (1995) Cellular interaction in germinal centers. Roles of CD40 ligand and B7-2 in established germinal centers. J. Immunol. 155, 556-567
45. + T cells and defective antibody production in vivo. J. Exp. Med. 179, 809-817
46. 46 Shi, F-D. et al. (1998) Differential requirements for CD28 and CD40 ligand in the induction of experimental autoimmune myasthenia gravis. Eur. J. Immunol 28, 3587-3593
47. 47 Hintzen, R.Q. et al. (1994) CD27: marker and mediator of T-cell activation? Immunol. Today 15, 307-311
48. 48 Goodwin, R.G. et al. (1993) Molecular and biological characterization of a ligand for CD27 defines a new family of cytokines with homology to tumor necrosis factor. Cell 73, 447-456
49. 49 Jacquot, S. et al. (1997) CD154/CD40 and CD270/CD27 interactions have different and sequential functions in T cell-dependent B cell responses: enhancement of plasma cell differentiation by CD27 signaling. J. Immunol. 159, 2652-2657
50. 50 Kobata, T. et al. (1995) CD27-CD70 interactions regulate B-cell activation by T cells. Proc. Natl. Acad. Sci. U. S. A. 92, 11249-11253
51. 51 Hartwig, U.F. et al. (1997) CD40 and IL-4 regulate murine CD27L expression. J. Immunol. 159, 6000-6008
52. 52 Santiago, M-L. et al. (1997) Interleukin-4 protects against a genetically linked lupus-like autoimmune syndrome. J. Exp. Med. 185, 65-70
53. 53 Zhang, G-X. et al. (1999) Mice with IFN-γ receptor deficiency are less susceptible to experimental autoimmune myasthenia gravis. J. Immunol. 3775-3781